Detection of Hepatitis C Core Antigen in the Antibody Negative ‘Window’ Phase of Hepatitis C Infection

Peterson, Julie A.; Green, G.; Iida, Kumiko; Caldwell, Burton V.; Kerrison, P.; Bernich, S.; Aoyagi, Katsumi; Lee, S.R.

doi:10.1046/j.1423-0410.2000.7820080.x

Cited by 78 publications

(83 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Good correlation (75%) was observed between assays of HCV core antigen and qualitative HCV RNA, in accordance with 71% in the early infection phase [22] , but the positive rate of the HCV core antigen ELISA was lower than previously reported rates of 87%, 88%, or 94% for other PWP specimens [24,25] . The discrepancy is likely due to the selection of early PWP plasma samples with lower HCV titers, or to the use of a highly sensitive qualitative RT-PCR method for single donations under well-controlled conditions [8,24,25] . Detection of HCV antibodies is commonly used in blood centers and plasma stations to reduce the transmission of HCV in China.…”

Section: Discussionsupporting

confidence: 80%

Detection of hepatitis C virus core antigen for early diagnosis of hepatitis C virus infection in plasma donor in China

Zhang¹,

Li²,

Wang³

et al. 2007

WJG

View full text Add to dashboard Cite

AIM:To evaluate the efficacy of a new hepatitis C virus (HCV) core antigen assay developed in China. METHODS:After the determination of HCV infection, 49 serial samples were selected from 11 regular plasma donors in 5 different plasma stations. To compare the performance of HCV core antigen detection and HCV PCR, these samples were genotyped, and each specimen was analyzed by ELISA for the detection of HCV core antigen and by qualitative HCV PCR. RESULTS:Among all of the sequential samples, the original 13 specimens were HCV RNA-negative, and 36 samples were HCV RNA-positive. Twenty-seven samples (75%) were HCV core antigen-positive from these HCV RNA-positive specimens. Conversely, 27 samples (93.1%) were found HCV RNA-positive in HCV core antigenpositive samples. Intervals between HCV RNA and HCV core antigen-positive, as well as between HCV core antigen-positive and HCV antibody-positive were 36.0 and 32.8 d, respectively. CONCLUSION:This HCV core antigen assay, developed in China, is able to detect much of anti-HCV-negative, HCV RNA-positive preseroconversion window period (PWP) plasma donations.

show abstract

Section: Discussionsupporting

confidence: 80%

Detection of hepatitis C virus core antigen for early diagnosis of hepatitis C virus infection in plasma donor in China

Zhang¹,

Li²,

Wang³

et al. 2007

WJG

View full text Add to dashboard Cite

show abstract

“…The first was developed by Tanaka et al (28) in 1995, and then Aoyagi et al (2) developed a new and 100-fold more sensitive test in 1999. In previously reported studies, HCV Ag was detected 1 day later than HCV RNA in patients undergoing seroconversion (5,6,20).…”

Section: Discussionmentioning

confidence: 77%

Comparison of a Newly Developed Automated and Quantitative Hepatitis C Virus (HCV) Core Antigen Test with the HCV RNA Assay for Clinical Usefulness in Confirming Anti-HCV Results

et al. 2011

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a global health care problem. Diagnosis of HCV infection is mainly based on the detection of anti-HCV antibodies as a screening test with serum samples. Recombinant immunoblot assays are used as supplemental tests and for the final detection and quantification of HCV RNA in confirmatory tests. In this study, we aimed to compare the HCV core antigen test with the HCV RNA assay for confirming anti-HCV results to determine whether the HCV core antigen test may be used as an alternative confirmatory test to the HCV RNA test and to assess the diagnostic values of the total HCV core antigen test by determining the diagnostic specificity and sensitivity rates compared with the HCV RNA test. Sera from a total of 212 treatment-naive patients were analyzed for anti-HCV and HCV core antigen both with the Abbott Architect test and with the molecular HCV RNA assay consisting of a reverse transcription-PCR method as a confirmatory test. The diagnostic sensitivity, specificity, and positive and negative predictive values of the HCV core antigen assay compared to the HCV RNA test were 96.3%, 100%, 100%, and 89.7%, respectively. The levels of HCV core antigen showed a good correlation with those from the HCV RNA quantification (r ‫؍‬ 0.907). In conclusion, the Architect HCV antigen assay is highly specific, sensitive, reliable, easy to perform, reproducible, cost-effective, and applicable as a screening, supplemental, and preconfirmatory test for anti-HCV assays used in laboratory procedures for the diagnosis of hepatitis C virus infection.

show abstract

“…24 Peterson et al reported that HCV core antigen appears substantially earlier than the HCV antibody during early phase of HCV infection and simultaneously with HCV RNA in most seroconversion series. 25 It became undetectable in a large proportion of seroconversion specimens after the development of anti HCV. 25 In our study we detected four HCV infected patients with core antigen ELISA and all these patients were anti HCV negative.…”

Section: Discussionmentioning

confidence: 99%

“…25 It became undetectable in a large proportion of seroconversion specimens after the development of anti HCV. 25 In our study we detected four HCV infected patients with core antigen ELISA and all these patients were anti HCV negative. Core antigen was negative in the 15 anti HCV positive specimens.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of HCV Infection in Patients on Haemodialysis: Survey by Antibody and Core Antigen Detection

Reddy¹,

Murthy²,

Lakshmi³

2005

Indian J Med Microbiol

View full text Add to dashboard Cite

Purpose: The present study was undertaken to determine the prevalence of HCV infection by antibody testing and HCV core antigen (HCVcAg) determination by ELISA in haemodialysis patients and to evaluate the HCV c Ag assay in the detection of HCV infected patients on haemodialysis. Materials and Methods: A total of 151 chronic renal failure patients on haemodialysis from May 2003 to October 2004 were studied. One hundred patients out of 151 were followed for 2-5 months. All the patients were tested for anti HCV and HCV core antigen once a month. Anti HCV ELISA positive specimens were confirmed by RIBA. Results: The overall prevalence of HCV infection was 13.23%. Antibody positivity was observed in 9.93% and HCVcAg alone was detected in 2.64%. One patient (0.66%) was initially positive for core antigen and later seroconverted. Conclusions: Screening for HCV antibodies alone does not exclude infection with HCV in patients on haemodialysis and HCVcAg may be a useful test for identifying HCV infected patients on haemodialysis in the early phase of infection before seroconversion.

show abstract

Detection of Hepatitis C Core Antigen in the Antibody Negative ‘Window’ Phase of Hepatitis C Infection

Cited by 78 publications

References 16 publications

Detection of hepatitis C virus core antigen for early diagnosis of hepatitis C virus infection in plasma donor in China

Detection of hepatitis C virus core antigen for early diagnosis of hepatitis C virus infection in plasma donor in China

Comparison of a Newly Developed Automated and Quantitative Hepatitis C Virus (HCV) Core Antigen Test with the HCV RNA Assay for Clinical Usefulness in Confirming Anti-HCV Results

Prevalence of HCV Infection in Patients on Haemodialysis: Survey by Antibody and Core Antigen Detection

Contact Info

Product

Resources

About